Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10945992 Dosage forms of rofecoxib and related methods

Patent 10945992 was granted and assigned to Tremeau Pharmaceuticals, Inc. on March, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

‌

Tremeau Pharmaceuticals, Inc.

Current Assignee

‌

Tremeau Pharmaceuticals, Inc.

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

109459920

Patent Inventor Names

Travis E. Helm0

Bradford C. Sippy0

Raymond D. Skwierczynski0

Date of Patent

March 16, 2021

Patent Application Number

168675140

Date Filed

May 5, 2020

Patent Citations Received

‌

US Patent 11872206 Purified forms of rofecoxib, methods of manufacture and use

‌

US Patent 11576890 Purified forms of rofecoxib, methods of manufacture and use

‌

US Patent 11617735 Purified forms of rofecoxib, methods of manufacture and use

‌

US Patent 11858909 Deuterated etoricoxib, methods of manufacture, and use thereof

‌

US Patent 11559509 Purified forms of rofecoxib, methods of manufacture and use

Patent Primary Examiner

‌

Svetlana M Ivanova

Patent abstract

The subject matter disclosed herein relates to novel doses and dosage forms of rofecoxib having a therapeutic benefit.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10945992 Dosage forms of rofecoxib and related methods

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API